Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...8586878889909192939495...123124»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. (Pubmed Central) -  Apr 23, 2021   
    P3
    Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor (clinicaltrials.gov) -  Apr 22, 2021   
    P1,  N=12, Active, not recruiting, 
    Trial completion date: Mar 2021 --> May 2022 Trial completion date: Jan 2021 --> Aug 2021 | Trial primary completion date: Dec 2018 --> Aug 2021
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  Post-Marketing Surveillance of Lenvima in Korean Patients (clinicaltrials.gov) -  Apr 22, 2021   
    P=N/A,  N=3000, Recruiting, 
    Trial completion date: Jan 2021 --> Aug 2021 | Trial primary completion date: Dec 2018 --> Aug 2021 Trial completion date: Oct 2021 --> Apr 2021 | Trial primary completion date: Oct 2021 --> Apr 2021
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal:  Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities. (Pubmed Central) -  Apr 22, 2021   
    A new generation of TKIs, specifically for single altered oncogenes, is under evaluation in phase 2 and 3 clinical trials. The aim of this review was to provide an overview of the current and future treatments of thyroid cancer with regards to the advanced and progressive cases that require systemic therapies that are becoming more and more targeted on the molecular identity of the tumor.
  • ||||||||||  everolimus / Generic mfg., lenvatinib / Generic mfg.
    Biomarker, Clinical, P2 data, Journal:  Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. (Pubmed Central) -  Apr 21, 2021   
    P1b/2
    The aim of this review was to provide an overview of the current and future treatments of thyroid cancer with regards to the advanced and progressive cases that require systemic therapies that are becoming more and more targeted on the molecular identity of the tumor. The 5-factor CBS may identify patients with metastatic RCC who would benefit from lenvatinib-plus-everolimus versus everolimus; additional validation is required.
  • ||||||||||  Mekinist (trametinib) / Novartis, BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Phase classification, Trial completion date, Trial primary completion date, Metastases:  Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors (clinicaltrials.gov) -  Apr 14, 2021   
    P2,  N=100, Recruiting, 
    Sorafenib after lenvatinib failure and sorafenib rechallenge may be a good option, but further prospective studies are needed. Phase classification: P=N/A --> P2 | Trial completion date: Jan 2023 --> Jan 2025 | Trial primary completion date: Jan 2022 --> Jan 2023
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Journal:  NOD2 inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway. (Pubmed Central) -  Apr 10, 2021   
    Moreover, we demonstrated that NOD2 activated AMPK pathway by directly binding with AMPKα-LKB1 complex, which led to autophagy-mediated apoptosis of HCC cells. Altogether, this study showed that NOD2 acted as a tumor suppressor as well as a chemotherapeutic regulator in HCC cells by directly activating AMPK pathway, which indicated a potential therapeutic strategy for HCC treatment by upregulating NOD2-AMPK signaling axis.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Symptomatic and asymptomatic biliary disorders during lenvatinib treatment for advanced thyroid cancer is an underestimated problem. (Pubmed Central) -  Apr 10, 2021   
    and our data the prevalence of this adverse event is of 16/118 (13.5%) and it seems independent from the starting daily dose. Only few differences have been observed: in our series some patients developed the adverse event even several months of treatment although the median time of onset was 3 months, some patients were asymptomatic and the disease was discovered at CT scan, some patients completely recover after the daily dose reduction and did not need to be operated.
  • ||||||||||  lenvatinib / Generic mfg.
    Biomarker, Retrospective data, Journal:  Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib. (Pubmed Central) -  Apr 10, 2021   
    Only few differences have been observed: in our series some patients developed the adverse event even several months of treatment although the median time of onset was 3 months, some patients were asymptomatic and the disease was discovered at CT scan, some patients completely recover after the daily dose reduction and did not need to be operated. Starting lenvatinib at BTS <42 mm should be recommended to achieve good treatment outcomes in patients with RR-DTC.
  • ||||||||||  Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal:  The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. (Pubmed Central) -  Apr 10, 2021   
    In this review, we focus on cabozantinib, a multikinase inhibitor which was proven effective in improving overall and progression-free survival of patients previously treated with sorafenib in the randomized Phase III CELESTIAL trial...In this review, we also make a particular mention to the use of cabozantinib in populations which are normally excluded from clinical trials, such as older patients and Child-Pugh B patients. Finally, we present the new treatment strategies in which cabozantinib is being tested, most notably the combination of cabozantinib and atezolizumab in the first-line setting in the phase III COSMIC-312 trial and the use of cabozantinib after progression on immune-checkpoint inhibitors.
  • ||||||||||  lenvatinib / Generic mfg.
    [VIRTUAL] Reversing lenvatinib resistance in liver cancer (Channel 3) -  Apr 10, 2021 - Abstract #EACR2021EACR_207;    
    P=N/A
    The encouraging results of the first 12 patients enrolled in this trial will be presented at the conference Conclusion Synthetic lethal genetic screens can help identify powerful drug combinations for drugs that have limited single agent activity. That synthetic lethal screens can lead to new clinical applications is also supported by the notion that our 2012 identification of synthetic lethality between BRAF and EGFR inhibitors in BRAF mutant colon cancer resulted in an EMA and FDA approval for this combination therapy in 2020.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Nexavar (sorafenib) / Bayer, Amgen
    [VIRTUAL] Molecular markers of response to anti-pd1 therapy in advanced hepatocellular carcinoma (Poster area) -  Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_730;    
    We identified an 11-gene signature of response to anti- PD1 therapy in first line advanced HCC, which was validated in other solid tumors. This signature did not identify responders after TKI treatment, thus calling for the need of biopsies prior to anti-PD1 therapy to enable biomarker-based precision oncology.